Morphological
evidence demonstrates the existence of dopaminergic afferent pathways and dopamine (DA)-containing neurons in the dorsal raphe nucleus (DRN). In a recent report, a DA D,-like receptor-mediated regulation of serotonin (5-HT) extracellular concentration in DRN has been found. Given the existence of somatodendritic 5-HT,, autoreceptors in the DRN, changes of the extracellular concentration of 5-HT in the vicinity of cell bodies and dendrites may be relevant for the control of the activity of ascending serotonergic pathways.
In the present brain microdialysis study we have used a chromatographic method (HPLC) enabling the simultaneous measurement of DA, 5-HT, and their main metabolites dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA). The presence of a neuronal pool of DA within the DRN was revealed by the local infusion of amphetamine (10 PM), which significantly increased the extracellular concentration of both amines. The local striatal infusion (10 PM) of the selective DA D,-like agonist SKF-38393, the selective DA D,-like agonist quinpirole (LY 171, 555) , or the nonselective DA agonist apomorphine markedly decreased DA and DOPAC extracellular concentrations and failed to modify 5-HT or 5-HIAA in the striatum, indicating the lack of terminal (striatal) control of 5-HT release by dopaminergic transmission. In contrast, the systemic administration of apomorphine (2.8 wmol/kg, s.c.) significantly increased the extracellular concentration of 5-HT in the DRN and decreased it in the striatum. The reduction of striatal 5-HT extracellular concentration was prevented by the previous administration of the selective 5-HT,, receptor antagonist WAY 100135 (17.6 rmol/kg, s.c.), which by itself did not change extracellular 5-HT in striatum. These results support that dopaminergic neurotransmission inhibits the activity of DRN-striatal neurons by increasing 5-HT extracellular concentration in DRN and, consequently, by increasing somatodendritic 5-HT,, autoreceptor stimulation in this nucleus.
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The dorsal raphe nucleus (DRN) (B6 and B7 areas of Dahlstrom and Fuxe, 1964 ) is a morphologically well-defined structure of the midbrain that contains, by far, the highest number and concentration of serotonergic (5HT) cell bodies of the mammalian brain (Wiklund et al., 198 1; Descarries et al., 1982) . Serotonergic neurons from the dorsal raphe project mainly to the basal ganglia, particularly the striatum (dorsal and ventral), the substantia nigra (SN), and the ventral tegmental area (VTA) (A9 and A10 areas of Dahlstrom and Fuxe, 1964 ) (Van der Kooy and Hattori, 1980; Herve et al., 1987) and to the frontal cortex (O'Hearn and Molliver, 1984) . These areas are involved in the parallel processing of motor function (Alexander and Crutcher, 1990) and are the source of and targets for the mesencephalic dopaminergic systems (Bjorklund and Lindvall, 1984) . These morphological data suggest that DRN serotonergic neurons modulate the function of brain dopaminergic systems. Indeed, dopamine (DA)-containing structures display moderate to high densities of several 5-HT receptor subtypes (5-HT,,,,,, 5-HT,, 5-HT,) (Pazos and Palacios, 1985; Pazos et al., 1985; Waeber et al., 1989 Waeber et al., , 1990 Hoyer, 1990) and there is functional evidence of a 5-HT-mediated regulation of mesencephalic dopaminergic systems, both at the somatodendritic (Nedergaard et al., 1988; Guan and McBride, 1989) and at the terminal level (Blandina et al., 1989; Benloucif and Galloway, 1991; Chen et al., 1991; Parsons and Justice, 1993) . Less is known, however, about a possible dopaminergic regulation of serotonergic DRN neurons, despite morphological evidence indicating the existence of projections from SN and VTA to the DRN (Afifi and Kaelber, 1965; Pasquier et al., 1977; Sakai et al., 1977; Lee and Geyer, 1984; KalCn et al., 1988) and of DA-containing neurons within the DRN (Hokfelt et al., 1976; Geffard et al., 1987; KalCn et al., 1988) . Also, the DRN contains a fairly high density of DA D,-like but not of DA D,-like receptors (Bouthenet et al., 1987; Palacios and Pazos, 1987) . Furthermore, electrophysiological studies have shown that the electrical stimulation of SN induces cessation of firing of DRN neurons (Stern et al., 1981 ; for review, see Aghajanian et al., 1987; Jacobs and Azmitia, 1992) .
The study of the complex interrelationships between both aminergic systems is relevant for understanding the serotonergic changes occurring in neurological diseases where DA is the transmitter primarily involved (e.g., Parkinson's disease) (Scatton et al., 1984; Cross, 1988) . Besides, DA-5-HT interactions are thought to play a role in the mechanism of action of atypical neuroleptics (Tamminga and Gerlach, 1987; Meltzer, 1992) and dopaminergic transmission appears to participate in the 3,4-methylenedioxyamphetamine (MDMA)-induced degeneration of serotonergic terminals (see McKenna and Peroutka, 1990, , 1993) . The existence of somatodendritic S-HT,, autoreceptors that inhibit electrical activity Aghajanian, 1987, 1988) S-HT synthesis (Hjorth and Magnusson, 1988; Hutson et al., 1989; Invernizzi et al., I99 I) , and 5-HT release in projection areas (Hutson et al., 1989; Sharp et al.. 1989a; Bonvento et al., 1992; Adell et al., 1993 ) is well documented Palacios, 1985: Verge et al., 1986; Sotelo et al., 1990) . Therefore, an increased dopaminergic transmission within the DRN may inhibit the activity of ascending DRN serotonergic neurons through an enhancement of 5-HT extracellular concentration in DRN and further activation of 5-HT,, autoreceptors. Indeed, pharmacologically induced increases of extracellular 5-HT in the raphe nuclei reduce terminal 5-HT synthesis and/or release, as measured with the push-pull cannula in the cat (Becquet et al., 1990) or in riro microdialysis in awake, freely moving rats (Adell and Artigas, I99 I).
In the present study, we have examined the effects of dopaminergic agents on extracellular 5-HT in the DRN and DA and 5-HT in the striatum. The data obtained support the view that Serotonergic cell bodies have been labeled with a "S-oligonucleotide directed against the 5-HT transporter mRNA by rn srtu hybridization as described elsewhere (Cartes et al., 1993) . C, Section through the striatum showing the track left by the microdialysis membrane (arrow).
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an increased dopaminergic activity results in opposite changes of extracellular 5-HT in DRN and striatum.
Materials and Methods
.4nima/s.
Male Wistar rats weighing 290-3 10 gm were used. They were housed four per cage and kept in a controlled environment (I 2 hr light/ dark cycle and 22 * 2°C room temperature). Food and water were provided ad libitum. Animal care followed the Spanish legislation on "Protection ofAnimals Used in Experimental and Other Scientific Purposes," in agreement with the European (E.E.C.) regulations (O.J. of E.C. L358/1 18/12/1986).
Surgery.
Concentric dialysis probes were made as previously described (Adell and Artigas, 1991) , with the exception that the length of the membrane exposed to the brain tissue was either I.5 mm or 4.0 mm long (0.25 mm o.d.). Before implantation, rats were anesthetized with so&urn pentobarbital (60 mg/kg, i.p.) and placed in a stereotaxic frame. Dialvsis probes (I.5 mm) were implanted in the DRN with a lateral angle of i@ and ihe following coordinates, in millimeters, with respect to bregma: AP -7.8, L 3. I, D -7.5 (Paxinos and Watson, 1982) . Dialysis (4 mm) probes were implanted in the striatum with the following coordinates, in millimeters, with respect to bregma: AP 0.2, L 3.0, D -8.0 (Paxinos and Watson, 1982) . The location of the dialysis probes is shown in Figure I .
Microdialvsis
procedure.
Animals were allowed to recover from surgery for approximately 18-20 hr and then probes were perfused with artificial cerebrosoinal fluid (125 mM NaCI. 2.5 mM KCI, 1.26 mM CaCI,, and I.18 AM MgCI,; PH 6.2) at 0.5 pl/min using a CMA/lOO microinjection pump (Carnegie Medicin, Stockholm, Sweden). Sample collection started 60 min after the beginning of perfusion. Usually four or five basal fractions were collected to obtain basal values before either local infusion or systemic administration of drugs. Local administration was performed by reverse dialysis. dissolving the appropriate amounts of each drug in the perfusion fluid. Systemic administrations were carried out subcutaneously using 5.5% glucose as vehicle (injection volume of 2 ml/kg). The effects of systemic apomorphine on extracellular 5-HT in DRN and striatum were performed in separate groups of rats. Given the small size of the I .5 mm dialysis probes, citalopram (I FM) was added to the artificial CSF to increase the detectability of serotonin when probes were implanted within the DRN. Successive 30 min (I 5 ~1) dialysate samples were collected. At the end of the experiment, the probe placement was verified by injection of methylene blue and visual inspection. Animals with a placement of the probe outside the DRN [indicated also by a low extracellular 5-hydroxyindoleacetic acid (5-HIAA) concentration; see Discussion] were discarded. The in vitro percentage recoveries of the 1.5 mm dialysis probes for DA, dihydroxyphenylacetic acid (DOPAC), 5-HT, and 5-HIAA were, respectively(flow rate = 0.5 pl/min), 20.1 -t 0.9, 21.9 -C 0.6, 23.8 i 1.8, and 18.3 + 0.8 (n = 4, mean + SEM). For the 4.0 mm dialysis probes these figures were, resnectivelv, 50.6 f 1.4. 42.2 + 1.2, 44.7 f 0.9, and 38.7 f 0.5 (n = 4, mean -f SEM). 0. I5 M NaH,PO,. 0.46 mM octyl sodium sulfate, 0.5 mM EDTA (pH 2.8 adjusted with phosphoric acid), and 18% methanol. The cathecol and indole compounds were separated on a 3 Km ODS 2 column (7.5 cm x 0.46 cm; Beckman. CA) and detected amperometrically with a Hewlett Packard 1049 detector, with a limit of detection of 0.5-l fmol for standard DA and 5-HT (Fig. 2) . This HPLC method enabled the simultaneous detection of DA, 5-HT. and their acidic metabolites in the Same dialysate samples.
Data an&is.
In each experiment, the results (expressed as means f SEM) are given as percentage of basal values. The statistical analysis -used was the "summary measures" method (Matthews et al., 1990) , using the mean of the four values previous to drug administration and the mean ofthe five values subsequent to drug administration per animal as the summary measures. Post-versus predrug values were compared using Student's paired t test to analyze drug effects. p values refer in all cases to these differences. 
Results
Basal dialysate concentrations of DA and 5-HT from the DRN (in the presence of 1 kmol/liter citalopram). taken as the mean ofthe two values preceding drug administration, were as follows (without adjusting for recovery): 1.4 + 0.1 nmol/liter for DA and 9.8 ? 2.2 nmol/liter for 5-HT (mean k SEM; n = 4 and 9 rats, respectively). Basal dialysate concentrations of DA, DO-PAC, 5-HT, and 5-HIAA from the striatum, taken as above, were (without adjusting for recovery) 15.9 ? 2.9 nmol/liter for DA, 16,429 ? 2136 nmol/liter for DOPAC, 1.2 t-0.2 nmol/ liter for 5-HT, and 1309 t 17 1 nmol/liter for 5-HIAA (mean -t SEM: IV = 12-25 rats). The occurrence of a neuronal pool of DA within the DRN was revealed by the local infusion of 10 wmol/liter amphetamine. This treatment enhanced DA and 5-HT extracellular concentrations (maximal increases +64% and +42%; Student's paired t test: p < 0.01 and p < 0.05, respectively) (Fig. 3) .
Continuous local infusion of 10 pmol/liter of the nonselective DA agonist apomorphine (Fig. 4) , the selective DA D,-like agonist SKF-38393 (Fig. 5) , or the selective DA D,-like agonist LY-17 1555 (quinpirole) (Fig. 6 ) induced a significant decrease in the striatal extracellular concentrations of DA (maximal reductions: -76%, -54%, and -62%, respectively; Student's paired t test, p < 0.01 in all cases) and DOPAC (up to -3O%, -32%, and -43%; Student's paired t test, p < 0.05 for apomorphine effect and p < 0.01 for SKF-38393 and quinpirole effects). Neither apomorphine, SKF-38393, nor quinpirole significantly altered the striatal extracellular concentrations of 5-HT or 5-HIAA when given locally.
The systemic administration of apomorphine (2.8 Fmol/kg, s.c.) induced a significant increase of DRN 5-HT extracellular concentration (maximal increase +75%; Student's paired t test, p < 0.0 I) and a significant decrease of 5-HT extracellular concentration in the striatum (up to -34%; Student's paired t test, JJ < 0.01) (Fig. 7) . In the same dialysate samples, DA concentrations decreased to about 40% of basal values in the striatum and to undetectable levels in most DRN samples.
To examine the involvement of 5-HT,, somatodendritic autoreceptors in these opposite changes of extracellular 5-HT in DRN and striatum, we used WAY 100135, a selective antag- onist of 5-HT,, pre-(somatodendritic) and postsynaptic receptors (Fletcher et al., 1993; Routledge et al., 1993 ). The treatment with WAY 100 135 alone (17.6 kmol/kg, s.c.) did not alter dialysate 5-HT or 5-HIAA in the striatum; yet the systemic (subcutaneous) pretreatment with WAY 100 135 prevented the reduction of striatal dialysate 5-HT elicited by apomorphine (Fig.  0 No overt behavioral effects were observed during local infusion of the different DA agonists, either in the DRN or in the striatum, or after systemic administration of WAY 100135. Stereotypies (mainly sniffing and licking) were observed after systemic administration of apomorphine and were not modified by the previous administration of WAY 100 135.
Discussion
Owing to the development of a new HPLC procedure, we have been able to determine low (0.5-l fmol) amounts of 5-HT and DA in the same dialysate samples from the DRN and striatum. This enabled the simultaneous study of both amines in the same animal. The HPLC method devised is particularly useful for the analysis of DA and 5-HT at very low concentrations, given their short retention times and the consequent increase in detectability. The present results demonstrate for the first time the occurrence of a measurable extracellular concentration of DA in the DRN. The somatodendritic or terminal origin of this DA is unclear, since both dopaminergic terminals from the SN or VTA (Afifi and Kaelber, 1965; Pasquier et al., 1977; Sakai et al., 1977; Lee and Geyer, 1984; Kaltn et al., 1988) and DAcontaining neurons within the DRN (HGkfelt et al., 1976; Geffard et al., 1987; KalCn et al., 1988) have been described. The present results cannot clarify this issue, since amphetamine releases both terminal and somatodendritic DA (Kalivas and Duffy, 1991; Robertson et al., 1991) . In any case, the increased extracellular DA after the local administration of amphetamine indicates the existence of a releasable pool of DA close to se- rotonergic cell bodies and dendrites in the DRN, a nucleus that contains a substantial density of DA D,-like receptors (Bouthenet et al., 1987; Palacios and Pazos, 1987) . This suggests that the DA-5-HT interaction found within the DRN in this and a previous study (FerrC and Artigas, 1993 ) may be physiologically relevant for the control of ascending serotonergic pathways. 5-HT extracellular concentration was also increased by the local application of amphetamine in the DRN. This is in accordance with data in the literature indicating an in viva releasing action ofamphetamine on 5-HT, as meas&d by microdialysis (Parada et al., 1988) although an indirect action caused by the increased DA may also contribute.
The basal concentration of extracellular 5-HT was not dependent on a precise position of the probe in the DRN, as observed in rats with an incorrect placement (not included in the study). In contrast, a high extracellular 5-HIAA concentration was a good indicator of the location of the probe within the boundaries ofthe DRN. This agrees with data showing that the basal extracellular concentration of 5-HT, as measured with microdialysis, is independent to a large extent on the density of innervation, thus reflecting the equilibrium between release and reuptake (Adell et al., 199 1; Jackson and Abercrombie, 1992) . However, since 5-HIAA lacks any reuptake system, its extracellular concentration is determined by its tissue content, higher in the raphe nuclei than in other brain areas (Adell et al., 199 1) .
The results obtained in this study extend previous observations indicating that (1) dopaminergic transmission increases extracellular 5-HT in the DRN, presumably through Dz-like receptors (Ferre and Artigas, 1993) and (2) the increased availability of 5-HT at somatodendritic 5-HT,, autoreceptors results in decreases of terminal serotonergic release (Becquet et al., 1990; Adell and Artigas, 199 1) .
In agreement with data in the literature, the striatal application of dopaminergic agonists induced a marked decrease of DA extracellular concentration. Thus, the local infusion of 10 pmol/liter of the nonselective DA receptor agonist apomorphine, the selective DA D,-like receptor agonist SKF-38393, or the selective DA D,-like receptor agonist quinpirole induced a strong and sustained decrease of striatal DA extracellular concentration. Similarly, DOPAC extracellular concentrations were significantly decreased by the local infusion of DA agonists. These reductions are most probably due to the activation of Dzlike release-inhibiting autoreceptors (by apomorphine and quinpirole) or postsynaptic D, -like receptors (by apomorphine and SKF 38393) located in striatonigral GABA neurons that control the activity ofnigrostriatal dopaminergic neurons (Imperato and Di Chiara, 1988; Reid et al., 1990; Fuxe et al., 1992) .
In contrast, striatal 5-HT and 5-HIAA extracellular concentrations in the same animals were unchanged after a dose (10 pmol/liter) of apomorphine and quinpirole that increased 5-HT concentration in DRN (FerrC and Artigas, 1993) . Hence, whereas 5-HT promotes DA striatal release when applied locally (Blandina et al., 1989; Benloucif and Galloway, 1991 ) the activation of dopaminergic D,-like and Dz-like receptors in the striatum does not result in local changes of 5-HT release. Clearly, this indicates an interaction of serotonergic transmission on terminal (striatal) dopaminergic function but not the opposite. Yet the local and systemic administration (this study) of the DA agonist apomorphine increased raphe extracellular 5-HT, an effect mediated by D,-like receptors in the DRN (FerrC and Artigas, 1993 ). An increased intra-and extracellular concentration of 5-HT in DRN, as measured by a histofluorescence method, has already been reported after the systemic treatment with apomorphine (Lee and Geyer, 1984) . However, these authors described a 1:3 ratio for extra-versus intracellular 5-HT, whereas it is widely accepted that this ratio is over 1: 1000 for most neurotransmitters (Westerink et al., 1987) in different brain areas, including 5-HT in the raphe nuclei (Adell et al., 1991) . Therefore, the relationship of the present in vivo results with the increased extracellular histofluorescence found by these authors is unclear. Also, apomorphine was reported to increase slightly (+ 12%) the striatal (but not the hippocampal) total tissue content of 5-HT (Lee, 1987) whereas a reduction of striatal extracellular 5-HT has been found herein. This discrepancy is likely to be due to the measurement of active (extracellular) and reserve (intracellular) pools when total tissue concentrations are involved. In contrast, only active pools of the transmitter are measured with the microdialysis technique.
The opposite changes ofextracellular 5-HT in DRN (increase) and striatum (decrease) induced by the systemic administration of apomorphine suggest that DA may inhibit the activity of ascending serotonergic pathways originating in the DRN via an increase of the extracellular concentration of 5-HT in DRN. Presumably, the reduction of striatal extracellular 5-HT results from the activation ofsomatodendritic 5-HT,, receptors located in DRN (Pazos and Palacios, 1985; Verge et al., 1986; Sotelo et al., 1990) secondary to the increase of 5-HT induced by apomorphine. Extracellular concentration of 5-HT in the midbrain raphe region is in the low nanomole/liter range (Adell et al., 1993) close to its affinity for 5-HT,, receptors (Pedigo et al., 198 1) . Hence, increases of 5-HT availability in the vicinity of serotonergic cell bodies and dendrites may result in decreased terminal synthesis and/or release, as shown previously (Becquet et al., 1990; Adell and Artigas, 1991) . Interestingly, the reduction of striatal extracellular 5-HT appears to be delayed with respect to the increase produced in DRN. This seems to be at variance with the fact that terminal 5-HT release increases shortly after the electric stimulation of the DRN (Sharp et al., 1989b (Sharp et al., , 1990 , indicating a firing-coupled release. However, the maximal reductions of terminal 5-HT output in frontal cortex or This delay has also been observed by Becquet et al. (1990) . These authors found a decreased 7H-5-HT release (newly synthesized from superfused 7H-tryptophan) in the caudate of cats during the perfusion of a 5-HT-releasing agent in the DRN. The reduced ?H-5-HT release in striatum persisted at least for 1 hr after the withdrawal of the 5-HT-releasing agent in DRN, a time when 5-HT release in DRN had almost regained normal levels. This is indicative that the diminished 5-HT terminal release may not be an immediate consequence of the suppression of firing at the somatodendritic level by 5-HT or 5-HT,, agonists (Blier et al., 1987; Sprouse and Aghajanian, 1987; Sinton and Fallon, 1988) and points toward a reduction of a terminal 5-HT releasable pool as a likely cause of the decreased 5-HT extracellular concentration in terminal areas. Indeed, 5-HT,, agonists markedly reduce terminal 5-HT synthesis when applied locally in the DRN (Hutson et al., 1989; Invernizzi et al., 199 l) , the striatum and prefrontal cortex being the two most sensitive brain areas (Invernizzi et al., 199 1) . That the reduction of extracellular 5-HT in the striatum following systemic administration of apomorphine may be secondary to the increase of 5-HT in the DRN is also supported by the lack of a local action of the dopaminergic agonists (see and the blockade of the effect with the systemic treatment with WAY 100135, a selective antagonist of pre-(somatodendritic) and postsynaptic 5-HT,, receptors (Fletcher et al., 1993; Routledge et al.. 1993) . At the dose used (17.6 pmol/ kg), this compound prevents the reduction of hippocampal5-HT release induced by the occupation of somatodendritic 5-HT,, receptors by the selective agonist &OH-DPAT (Routledge et al., 1993; Romero et al., unpublished observations). The injection of WAY 100135 alone did not modify the basal 5-HT output in striatum. This agrees with previous reports indicating that , autoreceptors in the DRN are not tonically activated (Innis and Aghajanian, 1987; Trulson and Frederickson, 1987; Becquet et al., 1990) .
Interestingly, Stern et al. (198 1) found an almost complete suppression of unit activity in DRN following electrical stimulation of the substantia nigra that, unlike that obtained by stimulation of the lateral habenula, could not be blocked by picrotoxin. This indicates the existence ofa functional inhibitory nigro-raphe pathway not involving GABAergic interneurons in the DRN. The results obtained in the present and previous (FerrC and Artigas, 1993) studies support the view that the excess 5-HT in the interstitial space in the DRN after dopaminergic D,-like activation may participate in the suppression of unit activity found previously (Stern et al., 1981) , through the hyperpolarization of serotonergic cells mediated by the opening of 5-HT,,-gated K+ channels (Innis and Aghajanian, 1987; HajDahmane et al., 199 1) .
In summary, the present results provide neurochemical support for an inhibitory dopaminergic control of ascending serotonergic pathways, mediated at the somatodendritic level (in DRN) through increases of the extracellular 5-HT concentration. The lack ofa local action ofdopaminergic agents precludes a DA-mediated control of striatal 5-HT release at the terminal level. The origin of the dopaminergic afferents responsible for these effects is uncertain and must await further studies.
